Galderma's rosacea treatment Mirvaso set for EU approval
This article was originally published in Scrip
Executive Summary
Following a nod from the US FDA in August, Galderma has received a positive opinion recommending the granting of a marketing authorization of Mirvaso (brimonidine tartrate 3 mg/g gel) from the EU's CHMP, for the symptomatic treatment of facial erythema of rosacea in adult patients.